Second cancer after additive chemotherapy in patients with colon cancer

• Verfasst von: Teufel, Andreas [VerfasserIn]
• Verfasst von: Li, Moying [VerfasserIn]
• Verfasst von: Gerken, Michael [VerfasserIn]
• Verfasst von: Ebert, Matthias [VerfasserIn]
• Verfasst von: Schlitt, Hans J [VerfasserIn]
• Verfasst von: Evert, Matthias [VerfasserIn]
• Verfasst von: Herr, Wolfgang [VerfasserIn]
• Verfasst von: Klinkhammer-Schalke, Monika [VerfasserIn]
• Titel: Second cancer after additive chemotherapy in patients with colon cancer
• Titelzusatz: original study
• Verf.angabe: Andreas Teufel, Moying Li, Michael Gerken, Matthias P. Ebert, Hans J Schlitt, Matthias Evert, Wolfgang Herr, Monika Klinkhammer-Schalke
• E-Jahr: 2022
• Jahr: 29 November 2022
• Umfang: 8 S.
• Fussnoten: Online verfügbar: 16 July 2022, Artikelversion: 29 November 2022 ; Gesehen am 26.06.2023
• Titel Quelle: Enthalten in: Clinical colorectal cancer and other gastrointestinal malignancies
• Ort Quelle: New York, NY [u.a.] : Elsevier, 2009
• Jahr Quelle: 2022
• Band/Heft Quelle: 21(2022), 4 vom: Dez., Seite 354-361
• ISSN Quelle: 1938-0674
• DOI: doi:10.1016/j.clcc.2022.07.002
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: 5-FU
• Sach-SW: Adjuvant chemotherapy
• Sach-SW: Adverse event
• Sach-SW: Cancer registry
• Sach-SW: oxaliplatin
• K10plus-PPN: 185101618X

Abstract

Background - Additive chemotherapeutic treatment of UICC-stage -III / IV colon cancer with fluorouracil, leucovorin and oxaliplatin is widely accepted as current standard of treatment after R0-resection. However, as patients.. survival is increasing, long-term side effects of chemotherapeutic agents such as second cancer development are becoming increasingly important. - Patients - We therefore investigated a total of 2 856 Patients with UICC-stage III / IV colon cancer, 223 of whom (7.8%) had developed a subsequent second cancer. - Results - Median follow-up was 73.2 months (range 209.9 months, 95%-CI 69.8-76.9). Most frequent second cancers were prostate cancer (18.4%), colon cancer (16.1%), breast cancers (8.1%), lung cancer (8.1%), rectal cancer (4.9%) and uterine cancer (4.9%). However, in comparison to non-treated patients this did not represent a significantly increased risk for subsequent second cancer in patients after treatment with additive chemotherapy. Of interest, our data suggest a significantly decreased second cancer rate in patients treated with FOLFOX compared to FUFOL for additive treatment. - Conclusions - Second cancer development was not increased after additive chemotherapy for colon cancer, which is a novel aspect in the ongoing discussions on reduction of adjuvant treatment to 3 months or treatment of lymph node negative patients. Novelty and Impact Statement To our knowledge, this is the first population-based study analyzing second cancer development after additive chemotherapy in patients with UICC III-IV colon cancer. The results have an important impact on the surveillance and long-term follow-up of cancer patients.